Amidst a backdrop of strengthening European indices, with Germany's DAX showing notable gains, investors are keenly observing market shifts and potential opportunities. In such a climate, identifying stocks that appear undervalued relative to their estimated fair values could offer attractive prospects for discerning investors.
Top 10 Undervalued Stocks Based On Cash Flows In Germany
Overview: Adesso SE operates as an IT service provider in Germany, Austria, Switzerland, and internationally, with a market capitalization of approximately €0.57 billion.
Operations: The company generates revenue primarily through two segments: IT Services (€1.31 billion) and IT Solutions (€119.88 million).
Estimated Discount To Fair Value: 15.2%
Adesso SE, priced at €87, is considered undervalued based on discounted cash flow analysis, with an estimated fair value of €102.61. Despite trading 15.2% below this valuation and showing potential with a forecasted annual revenue growth of 11.9%, its financial robustness is questionable as earnings barely cover interest payments. Profitability is expected within three years, yet the projected return on equity remains modest at 13.6%. Recent engagements include presentations at Big Data & AI World Frankfurt, highlighting its active role in data-driven sectors.
Overview: Adidas AG operates globally, designing, developing, producing, and marketing athletic and sports lifestyle products across various regions, with a market capitalization of approximately €39.51 billion.
Operations: The company generates revenue from several geographic segments, with €5.16 billion from North America, €3.20 billion from Greater China, and €2.31 billion from Latin America.
Estimated Discount To Fair Value: 34.8%
Adidas AG, currently trading at €221.3, is significantly undervalued with a DCF-based fair value of €339.51, reflecting a 34.8% discount. After turning profitable this year with first-quarter sales rising to €5.46 billion from €5.27 billion and net income hitting €170 million against last year's loss, the outlook is bullish. Earnings are expected to surge by 41.3% annually over the next three years, outpacing the German market forecast of 18.7%. Recent presentations in Stockholm and upcoming events in Paris and Warsaw underscore its active market engagement.
Overview: Gerresheimer AG operates globally, specializing in the production and sale of medical packaging and drug delivery devices, with a market capitalization of approximately €3.56 billion.
Operations: The company generates revenue through three main segments: Plastics & Devices (€1.09 billion), Advanced Technologies (€6.43 million), and Primary Packaging Glass (€908.16 million).
Estimated Discount To Fair Value: 21.7%
Gerresheimer AG, priced at €103, is considered undervalued with a DCF valuation of €131.55, suggesting a 21.7% potential upside. While its revenue growth is slower compared to some market segments at 10.3% annually, earnings are expected to increase significantly by 20.41% per year over the next three years, outpacing the broader German market's forecast of 18.7%. However, it carries a high level of debt and its Return on Equity is projected to be low at 13.8%. Recent activities include an earnings guidance update projecting up to 15% revenue growth by 2025 and consistent profit growth in Q1 reports for 2024.
Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
